Emerging Molecular Targets in MASH/NASH: Linking Pathogenic Mechanisms to Therapeutic Strategies for Improved Pharmacological Management. (PubMed, Curr Mol Med) - Oct 15, 2026 - "Cyclophilin inhibitors (CRV431, NV556) demonstrate anti-fibrotic efficacy in Phase 2A trials by targeting mitochondrial dysfunction and collagen synthesis. ACLY inhibition offers advantages over acetyl-CoA carboxylase targeting by upstream modulation of de novo lipogenesis, with bempedoic acid showing clinical promise...FXR agonists (obeticholic acid, cilofexor, tropifexor) demonstrate robust clinical efficacy in improving steatosis, inflammation, and fibrosis. Chemokine receptor antagonists (cenicriviroc, AZD5069) show potential in reducing inflammatory cell recruitment, though mixed clinical results highlight the complexity of immune modulation...The advanced clinical development of several candidates, particularly FXR agonists and cyclophilin inhibitors, suggests near-term therapeutic breakthroughs. Future combination therapies targeting multiple pathways simultaneously may optimize treatment efficacy for this multifaceted disease."
Journal • Fibrosis • Hepatology • Immune Modulation • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • IL1B • NLRP3 • XBP1
|
|
Siddhant; Abhijit Debnath; Anu Chandran; Kaif Khan Ashpak Pathan; Rajesh Kumar Singh; Sk Ashif Jan
|